News

According to the strategic collaboration, Mylan gains rights to develop and market Biocon’s Glargine, Lispro and Aspart. Glargine, Lispro and Aspart are the generic equivalents to Sanofi’s Lantus,

K&L, which provides end-to-end services for all types of clinical studies, said it is planning to expand its capabilities in the US, Asia and the Pacific region, especially

Under the agreement, Boehringer will implement ChemAxon’s chemistry software platform for use in multiple applications across research and development, supporting in-house activities and work with external collaboration partners.

Prior to joining the company, Adams served at Auxilium Pharmaceuticals as chief executive officer and president and at Neurologix as chairman and chief executive officer. Adams also worked

According to the deal, Cellmid will receive initial fee besides additional payment if Fujikura decides on exercising its license option. Upon any future sales of midkine diagnostic products

The patent entitled, ‘Abuse-Deterrent Drug Formulation’, covers Oxycodone DETERx (COL-003) product which utilizes the company’s proprietary DETERx drug delivery technology. Currently in the final stage of clinical development,

The application covers a drug delivery system based on the company’s Smart Surface technology, which electronically or manually controls the dispensing of a fluid on a nano-structured surface.

Mesoblast will supply MPCs manufactured at Singapore manufacturing facility of its contract manufacturer, Lonza, besides at its US facility. Mesoblast chief executive Professor Silviu Itescu said, "Having multiple

The progression of the compound into pre-clinical development has triggered a milestone payment to Evotec from Ono, as per the deal signed between the companies in March 2008.